The HER2/neu antibody trastuzumab induces tumour regression in approximately 30 – 35% of patients with HER2-amplified metastatic breast cancer (Hsieh and Moasser, 2007), indicating that additional signalling molecules may influence the biological response to trastuzumab. Here, ERBB2 is linked to neoplasm.